Responses
Clinical/translational cancer immunotherapy
Original research
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
Compose a Response to This Article
Other responses
No responses have been published for this article.